pharmaphorum Podcast

In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on systems and infrastructure designed to connect ideas, people, and expertise across sectors. Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly that goal in mind. Bringing the NHS,...

Boehringer Ingelheim’s data presented at ASCO 2025 reflected the company’s broad pipeline and growing body of evidence supporting innovative therapies for various cancers. In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head of oncology at Boehringer Ingelheim, for a discussion of the unmet needs in oncology and some of the s...

Trends can be predicted, and trends can unfold. Here, Liz Beatty – co-founder and chief strategy of Inato – speaks to the beginnings of a new era in drug development brought on by key technological advances in AI. Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as inaccessibility, lack of representation, and intense competition for...

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and diseases like whooping cough and measles have seen a worrying resurgence due to anti-vaxxers. And not just in the US. In a new pharmaphorum podcast, Rebecca Catterick, General Manager for Vaccines, UK & Ireland, at Sanofi, discusses this decline in vaccination rates, as...

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals, a company that has been serving as a regional affiliate for pharma and biotech since 1981 in the CEE and Mediterranean. Market access strategies in many international mark...

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face in the year ahead. Host Nicole Raleigh is joined by Cencora’s Sandra Anderson, SVP of International Commercialisation, and Chris Williams, SVP &...

ISPOR 2025, the leading global conference for Health Economics and Outcomes Research (HEOR), takes place 13th-16th May and marks the 30th anniversary of the organisation. Ahead of the event, web editor Nicole Raleigh spoke with Rob Abbott, CEO and executive director of ISPOR – the leading professional society for HEOR globally – about the ins and outs and trends of HEOR. ISPOR’s mission is to adva...

President Donald Trump’s April 15th executive order, “Lowering Drug Prices by Once Again Putting Americans First”, contained a smorgasbord of policy proposals targeting a variety of industry stakeholders. But how much legal force do these different elements have, and what are the concrete takeaways for pharma? To answer these questions and more, host Jonah Comstock once again welcomes Hogan Lovell...

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: innovation in drug development is lagging behind. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn. AI, about how the real hurdle in clinical research lies in effectively integra...

Therapy initiation, adherence, and health outcomes are being driven by artificial intelligence (AI)-powered personalisation. Today’s consumers are more active participants in their healthcare. Marketing in the era of consumer-driven healthcare requires new strategies to reach patients with the information they require, and how and when they need it. In a new pharmaphorum podcast, web editor Nicole...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostriezewski, CSO at CN Bio, about single organ-on-a-chip technology and multi-organ microphysiological systems (MPS), as well as accelerating drug discovery pipelines with these new alternative methodologies (NAMs). Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease stat...

Across the life sciences, Regulatory Affairs (RA) teams and their colleagues in Quality and Safety are stretched beyond their limits as already impossible demands on their time are compounded by rising health authority expectations. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sonia A. Veluchamy, CEO and co-founder of Celegence, a company dedicated to improving patient outc...

In a new pharmaphorum podcast, recorded during Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine, about the role of prevention in the future of healthcare. Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The Prevention Revolution in Your Healthcare’, exploring th...

As we hear of the volcanic and seismic activity taking place in Iceland this week, pharmaphorum turns back to a conversation with Dean Alms, CPO of Aravo, on how extreme weather highlights the need to make adequate supply chain preparations for the seasons in which the planet pulls out all the stops with the worst of its natural disasters. Having a blueprint for supply chain resiliency is critical...

If we don’t address the mental health of young people, that mental health challenge will advance into the adult population of tomorrow. What can be done to address the issue, though? At Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh sat down with Dr Sebastian Vaughn, CEO of Phytome Life Sciences, for an en plein air and explorative conversation around the topic, live onsite at The Ede...

Last year, Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert in Washington, D.C. joined host Jonah Comstock on the pharmaphorum podcast to talk about the intended and unintended consequences of the drug pricing negotiation provisions in the Inflation Reduction Act. On today’s episode, Curran joins us once again for an update on the IRA, looking at the second batch of d...

It takes around seven years to develop a new drug and bring it to market. With the advent of GenAI, businesses in the life sciences sector can speed up the process, wiping months or even years off that average. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bryan Hill, life sciences chief technology officer at Cognizant, in a conversation on how generative AI is revolutionisi...

Unique, patient-focused manufacturing models are needed to scale up innovative cell therapies for cancer and one company, CTMC, is challenging the status quo to achieve this and get them to patients. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine aiming to advance novel scientific breakthroughs in...

Prior authorisations (or PAs) have long put a burden on pharmacy and medical practices, ultimately causing delays for patients.  In a new podcast, web editor Nicole Raleigh speaks with Andrew Burns, chief revenue officer at DrFirst, about the ramifications of delayed patient care when it comes to specialty medications. Exploring the current PA landscape, the conversation touches upon specialty pha...

Around 75% of rare diseases are diagnosed in childhood, with most before the age of two. With 30% of rare disease patients dying before the age of five, the need for different treatment methods for children is clear. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Helen Thackray, chief R&D officer at biotech company BioCryst, as well as an alumnus of the Children’s Nati...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D processes to unleash the next wave of biopharma breakthroughs. PharmaLex’s Dr Christian Schneider, VP & Chief Medical Officer, Clinical Development Services, together with Dr Christelle Boileau, Director of Regulatory Development Strategy and IPD solution lead at PharmaLe...

The JP Morgan Healthcare Conference remains one of the most influential events for the life sciences sector, setting the stage for major deal-making, investment trends, and strategic shifts that will define the year ahead. Keen to capture all the key trends and talking points from this year’s event, pharmaphorum editor-in-chief, Jonah Comstock, hit the ground running in Philadelphia,  live bloggin...

Therapeutic antibodies are a vital weapon in combating diseases such as cancer, but developing these treatments through conventional methods is slow and unreliable. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Dr James Field, founder and CEO of LabGenius, a drug discovery company pioneering the discovery of next-generation therapeutic antibodies in order to solve this predic...

AI might still be in the modish buzzword stage, but discussions exploring the potential for its scaling within life sciences are critical. In a new pharmaphorum podcast with ZS Associates’ Sharon Karlsberg, principal and leader of oncology solutions, and Brandi Davis-Dusenbery, principal and partner, web editor Nicole Raleigh explores the potential for scaling advanced technologies in the biopharm...

For women with rare diseases, they often face a double jeopardy, where many of the symptoms they experience can be confused with and misdiagnosed as menopause. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz, head of rare diseases at Ipsen, for a conversation focused on rare liver disease primary biliary cholangitis (PBC), which affects nine women for every on...